癲癇發(fā)作可能導(dǎo)致無(wú)法控制的肢體運(yùn)動(dòng)，異常的思維和行為，以及異常感知。肢體運(yùn)動(dòng)可能非常劇烈，并導(dǎo)致喪失意識(shí)。癲癇的產(chǎn)生是由于大腦中的一群神經(jīng)細(xì)胞不受控制地被激活，局灶性癲癇指的是癲癇發(fā)作起源于大腦中有限的部分腦區(qū)。 Xcopri是SK Life Science公司自主研發(fā)，治療癲癇的創(chuàng)新療法。它被認(rèn)為可以通過(guò)抑制電壓門(mén)控鈉電流以及通過(guò)異構(gòu)作用正向調(diào)節(jié)GABAA受體活性，減少神經(jīng)細(xì)胞重復(fù)釋放電沖動(dòng)。
參考資料：
[1] FDA approves new treatment for adults with partial-onset seizures. Retrieved November 21, 2019, from https://www.prnewswire.com/news-releases/fda-approves-new-treatment-for-adults-with-partial-onset-seizures-300963454.html
[2] Results of a Randomized Study of the Safety and Efficacy of Cenobamate in Adults with Uncontrolled Focal Seizures Published in The Lancet Neurology. Retrieved November 21, 2019, from https://www.sklifescienceinc.com/pdf/Results%20of%20a%20Randomized%20Study%20of%20the%20Safety%20and%20Efficacy%20of%20Cenobamate%20in%20Adults%20with%20Uncontrolled%20Focal%20Seizures%20Published%20in%20The%20Lancet%20Neurology.pdf
